Drug Development
Sequella Receives American Recovery and Reinvestment Funding Through the NIH
Published in TB and Outbreaks Week, October 20th, 2009
Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009. The ARRA funds, issued through the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), will assist Sequella to complete the manufacture of its lead drug candidate, SQ109, and provide drug supplies to continue NIH grant-funded research on SQ109 mechanism of action.
SQ109 is a new small molecule drug that is currently under US IND for the treatment...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Stanford University Medical Center
Stanford analyses of flu pandemics project savings from earlier vaccinations - University of Texas Health Science Center at Houston
New chemically activated antigen could expedite development of HIV vaccine - Bird Flu
Research from Zhejiang University provides new data about bird flu - Bird Flu
Scientists at Alabama State University detail research in bird flu - Central Nervous System Infection
Reports outline central nervous system infection study results from J. Dassarma et al - Clinical Infectious Diseases
New clinical infectious diseases study findings reported from Chang Gung Memorial Hospital - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
